Seres Therapeutics Inc (MCRB) Stock Price, Quote & News

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 9626

Website: www.serestherapeutics.com

Address:

101 Cambridgepark Drive, Cambridge, United States

ryu1288 Dec. 4 at 9:21 PM

$MCRB Just to add. The translationial biomarker data from early janaury was for ser-155 in allo-hsct. Although it's MOA also shows promise for application in UC, Crohns, the biomarker data wasn't derived from a relevant population that is akin to those indications. The IST trial while although phase 1 and a small trial, is in a relevant population--irEC. If the data is strong it can support and further validate that Ser-155 can be used as a paltform for these other indications. Seres announced this IST trial in august's Q2 call, the first call with co-ceos, after Shaff stepped down. Also Seres made some cost cutting decisions to extend cash runway into Q2 2026, the IST data is expected ealry 2026. Those cost cutting measures were effective in August as well. Could these steps have been taken as a bridge to this IST data, could it strengthen Sere's leverage in potential parnership/acquistion talks if the data is strong?

0 · Reply

MoneyGroupLLC Dec. 4 at 6:49 PM

Enter: $MCRB Calls Strike Price: $18 Expiry Date: JAN 16 2026 Buy in Price: $3.40 - $4.40 Sell Price: $7.21 Profit : +112% (Turn every $1 into $2.12) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

ryu1288 Dec. 4 at 6:47 PM

$MCRB New here, just my thoughts, fyi im not a seasoned investor or expert: Could the the trial being paid for by memorial sloan carry more weight and is going unoticed of how important it actually is? Right now we only have biomarker information which indciates the scope Ser-155 has for a variety of potenial indications, ie crohns, uc, etc, which are beyond what it is currently indicated for. This paid for trial by memorial sloan is a phase 1 trial and it can support viewing or valdiating the platform potential for ser-155 further than the biomarker data from early this year. Could this be value creating, platform valdiating, and perception changing for mcrb? Are we waiting for these results, if so end febuary/march seems like the timeframe to get them. Again im a noob, just wanted to share my thoughts.

1 · Reply

Rawbinhood Dec. 4 at 5:52 PM

$MCRB It's been a long time since we had 200,000 shares available to short, May 7th 2025 to be exact!

1 · Reply

TotalChamp Dec. 4 at 4:56 PM

$MCRB we won’t hear any news until mid January. Just hang in there

1 · Reply

Iightning Dec. 4 at 8:11 AM

1ightning® Premium Options Alert (Actionable) Ticker: $MCRB Contract: Dec 19 $17.5C Entry: 2.00 Exit: 3.01 Return: +50.70% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HedgeAlerts Dec. 4 at 6:29 AM

Hedge Alert Live - Protect Your Portfolio Contract: $MCRB $15.00 Put · DEC 19, 2025 Exp Entry Price: $1.70 - $1.85 Exit Price Target: $3.76 Profit Margin: +103% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

TradeStockWell Dec. 4 at 2:27 AM

$MCRB 150-160$ per share. this is an excellent case study on retail investors. So much data on this board. 2¢

2 · Reply

LiquidThetaOptions Dec. 4 at 1:48 AM

💎 LiquidTheta® Live Actionable Trade Asset: $MCRB Contracts: $MCRB January 15, 2027 $18 Calls Scale in: $6.05- $7.40 Scale out: $23.54-$40.35 Profit Potential : 210% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

MoneyGroupLLC Dec. 3 at 11:56 AM

Enter: $MCRB Calls Strike Price: $20 Expiry Date: JAN 16 2026 Buy in Price: $2.50 - $2.62 Sell Price: $4.10 Profit : +64% (Turn every $1 into $1.64) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 5, 2025, 2:11 PM EST - 4 weeks ago

Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 5 weeks ago

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Sep 23, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Sep 22, 2025, 12:10 PM EDT - 2 months ago

More companies adopt co-CEO structure

IREN KKR LEN NFLX ORCL SBET

Aug 27, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 9:47 PM EDT - 4 months ago

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:23 PM EDT - 4 months ago

Seres (MCRB) Q2 Loss Narrows 34%

Aug 6, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SANA

Jul 29, 2025, 2:09 PM EDT - 4 months ago

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Jul 22, 2025, 7:01 AM EDT - 4 months ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Jul 22, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Announces Leadership Transition

May 27, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 7, 2025, 2:18 PM EDT - 7 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 7 months ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 23, 2025, 7:00 AM EDT - 8 months ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Mar 13, 2025, 11:04 AM EDT - 9 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 9 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 7:00 AM EST - 9 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 3, 2025, 7:00 AM EST - 9 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Jan 16, 2025, 7:00 AM EST - 11 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 9, 2025, 7:00 AM EST - 11 months ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Dec 16, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Nov 13, 2024, 10:28 AM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024, 5:15 PM EDT - 1 year ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 27, 2024, 3:26 PM EDT - 1 year ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024, 4:01 PM EDT - 1 year ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 23, 2024, 12:14 AM EDT - 1 year ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024, 3:35 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Jun 7, 2024, 4:00 PM EDT - 1 year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 6:30 AM EDT - 1 year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 11, 2024, 5:34 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 9:30 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Mar 5, 2024, 3:33 PM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

ryu1288 Dec. 4 at 9:21 PM

0 · Reply

MoneyGroupLLC Dec. 4 at 6:49 PM

0 · Reply

ryu1288 Dec. 4 at 6:47 PM

1 · Reply

Rawbinhood Dec. 4 at 5:52 PM

$MCRB It's been a long time since we had 200,000 shares available to short, May 7th 2025 to be exact!

1 · Reply

TotalChamp Dec. 4 at 4:56 PM

$MCRB we won’t hear any news until mid January. Just hang in there

1 · Reply

Iightning Dec. 4 at 8:11 AM

1ightning® Premium Options Alert (Actionable) Ticker: $MCRB Contract: Dec 19 $17.5C Entry: 2.00 Exit: 3.01 Return: +50.70% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HedgeAlerts Dec. 4 at 6:29 AM

0 · Reply

TradeStockWell Dec. 4 at 2:27 AM

$MCRB 150-160$ per share. this is an excellent case study on retail investors. So much data on this board. 2¢

2 · Reply

LiquidThetaOptions Dec. 4 at 1:48 AM

0 · Reply

MoneyGroupLLC Dec. 3 at 11:56 AM

0 · Reply

Tritsortreat2020 Dec. 3 at 11:29 AM

$MCRB last time kim chido ”john doe” chimed in, we went on a 100+% run. now shes back talking about weird stuff again. buckle your seatbelts boys and girls . this is my strategy and im sticking to it 😂

2 · Reply

mongoosereflexes Dec. 3 at 10:39 AM

$MCRB if they keep going to investor conferences and they keep saying the same thing over and over again one can only logically assume they don’t have anything lined up yet…

2 · Reply

Fairvalue10 Dec. 3 at 9:57 AM

$MCRB Can't find the volume after hours ... ?

0 · Reply

coreholder Dec. 3 at 5:10 AM

$MCRB 😂👊🏼👌

0 · Reply

LionNoRichy Dec. 2 at 10:55 PM

$MCRB buy it and end it xd this feels like a ticking bomb no tim

0 · Reply

Cveets Dec. 2 at 9:24 PM

$MCRB Actively in discussions, sounds like a nice TAM as well. I’ll stay here and wait for the Partnership announcement. Hopefully soon!? 🤞

1 · Reply

KIMCHIDOE Dec. 2 at 9:23 PM

$MCRB What the hell are they doing with two CEOs? Getting a CEO salary? I'm tired of being fuxked up with magical midget

0 · Reply

jamstah Dec. 2 at 7:14 PM

$MCRB so an interesting presentation, on IBD they said they have two research collaboration partners they are talking to. That typically means someone like Crohns and Colitis foundation, NIH, Helmsley Trust and ECCO and possible in partnership with a research insitute such as MSK/ a university. Typically not a huge amount of funding given. C&C foundation has given money to Seres in the past

0 · Reply

SenefAS Dec. 2 at 4:14 PM

$MCRB Nothing new in the presentation of the day ?

1 · Reply

LionNoRichy Dec. 2 at 4:03 PM

$MCRB nothing burger indeed, they should have stayed home talking to Nestle

1 · Reply

Fairvalue10 Dec. 2 at 3:58 PM

$MCRB "So our goal would be to be operationally ready pending the receipt of financing, to really be able to to get into the clinic in the phase two as, as quickly as possible " Ok .... sell it

0 · Reply

LionNoRichy Dec. 2 at 3:53 PM

$MCRB "we have" with whom you wanna partner 🫠

0 · Reply

Market Cap	151.08M
Revenue (ttm)	0.00
Net Income (ttm)	140,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	115,995
Avg Vol	195,898
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	8%
Beta	0.18
Analysts	Sell
Price Target	$16.00